BCG Report on Using RWE in Clinical Trials

May 5, 2021

A Boston Consulting Group (BCG) report discusses the benefits of real world evidence (RWE) in streamlining the clinical trial pipeline. RWE has been used in synthetic control arms (SCAs), leading to reduced costs and faster FDA approval. The report also includes several ongoing challenges related to RWE, such identifying and utilizing a robust data source, standardizing statistical methods, and recruiting talent. The report discusses solutions to these challenges that will ultimately lead to better healthcare outcomes.

According to the report, “The prerequisites for using SCAs in clinical trials are quickly coming together, while promising initiatives and examples have demonstrated the value. Now is the time for the R&D departments of pharma companies to identify their specific opportunities and gain experience in this critical area. Although the effort is significant, so too is the reward: accelerating the delivery of safe and efficacious drugs to the patients who need them.” Read more here.

(Source: Fraterman et al., BCG, 2/17/21)

Share This Story!